

GOOD VETERINARY PHARMACOVIGILANCE PRACTICE GUIDE

Foreword

This IFAH-Europe¹ Good Veterinary Pharmacovigilance Practice Guide is a very good illustration of the animal health industry initiatives to promote veterinary pharmacovigilance and it is a great pleasure to see its second edition coming off the press.

The first edition, launched in March 2004, was elaborated following a joint workshop with competent authorities and veterinarians (FVE²) in May 2002. Veterinary pharmacovigilance has since come a long way and IFAH-Europe undertook this revision to reflect the changes to the regulatory environment. While most sections of the GVPPG have been updated to a certain extent, the main changes relate to the addition of the following new references: Detailed Description of the Pharmacovigilance System; the initiative on Periodic Safety Update Reports synchronisation and work-sharing; electronic reporting and pharmacovigilance inspection.

Thus, this Good Practice Guide provides a useful tool for anyone in industry involved in veterinary pharmacovigilance. It should be read in conjunction with the legal texts, but does not bind industry or the relevant authorities or any other party involved.

Finally, I wish to express special thanks to the IFAH-Europe Pharmacovigilance Working Party for its contribution to the release of this 2nd edition and the European competent authorities who responded positively to this industry initiative.

Brussels, April 2011



Sylvie Meilleris
Technical Project Manager
IFAH-Europe

¹ IFAH-Europe International Federation for Animal Health - Europe <http://www.ifaheurope.org/>

² FVE Federation of Veterinarians of Europe <http://www.fve.org/>

About IFAH-Europe

IFAH-Europe (International Federation for Animal Health-Europe) is the federation representing manufacturers of veterinary medicines, vaccines and other animal health products in Europe. It represents both corporate members and national animal health associations in Europe. These associations comprise both local, small and medium-sized enterprises (SMEs) and international companies. IFAH-Europe's membership covers 90% of the European market for veterinary products.

Mission

IFAH-Europe's mission is to promote a predictable, harmonised, science-based marketplace for the provision of innovative, quality, animal health products that contribute to the supply of safe, healthy food and to high standard of health and welfare for animals and people.

As a responsible industry, we want to ensure that our stakeholders understand the work we do and the broad range of benefits we provide for society at large. To achieve this, as the voice of the European animal health industry, we encourage constructive dialogue with governments, public policy makers, legislators, regulators, non-governmental organisations, the veterinary profession, the food chain, consumers and other stakeholders.



TABLE OF CONTENTS

1. INTRODUCTION: THE IMPORTANCE OF GOOD PHARMACOVIGILANCE PRACTICE	9
2. THE EUROPEAN PHARMACOVIGILANCE FRAMEWORK	10
2.1 What is the right terminology for suspected adverse reactions?	10
2.2 Where can the relevant legal texts be found?	10
2.3 What are the legal obligations of an animal health company?	10
2.4 Who are the different stakeholders in veterinary pharmacovigilance?	11
2.5 What is the geographical area in which EU pharmacovigilance rules apply?	11
2.6 Is there a flow chart or decision tree available that reflects the reporting of Adverse Events in veterinary pharmacovigilance?	11
3. PHARMACOVIGILANCE CASES	13
3.1 Adverse event: definition, scope and need to report	13
3.1.1 Definition	13
3.1.1.1 What is an adverse event?	13
3.1.1.2 Is the scope of veterinary pharmacovigilance limited to reporting of AEs?	13
3.1.1.3 Does the use of the wording ‘adverse events’ imply that only reactions for which the company considers there is a possible causality link need to be reported to the Competent Authority?	13
3.1.1.4 What are the minimum data components that make an observation/report an AE report?	13
3.1.1.5 Are there different types of AEs (apart from the scope)?	14
3.1.1.6 What are ‘unexpected’ and ‘expected’ AEs?	14
3.1.1.7 What is a ‘serious AE’?	14
3.1.1.8 How is the word ‘serious’ interpreted for each type of animal?	14
3.1.1.9 Is every unintended and harmful observation after an off-label use of the product reportable as an AE?	14
3.1.1.10 Are bad in-vitro sensitivity data to be reported as AEs?	14
3.1.1.11 Must an event be product-related to be called an AE?	15
3.1.1.12 Are quality defects to be reported as AEs?	15
3.1.1.13 Are asymptomatic human exposures reported to the company considered as AEs?	15
3.1.2 Investigation and reporting of a reported AE by a company	15
3.1.2.1 What are the basics a company needs to do when receiving an AE report?	15
3.1.2.2 Do all AEs need to be RECORDED?	15
3.1.2.3 Do all AEs need to be REPORTED?	15
3.1.2.4 What is the general rule on reporting?	15

3.1.2.5 Is the date by which the four minimal data components are met important for an AE report?	16
3.1.2.6 How should serious AEs be dealt with in general?	16
3.1.2.7 Do all AEs need investigating?	16
3.1.2.8 Do serious AEs need much closer investigation?	16
3.1.2.9 Are reports concerning the validity of the withdrawal period (residues above the MRL) to be reported as serious AEs?	16
3.1.2.10 How should reports on environmental cases be handled?	16
3.1.2.11 How should mortality in a Suspected Lack of Expected Efficacy (SLEE) case be handled?	17
3.1.2.12 What about AEs following the use of a veterinary premix?	17
3.1.2.13 What about reporting AEs for generic, copy cat and co-distributed products?	17
3.1.2.14 Do AEs that have already been reported directly to the authorities (e.g. by a veterinarian or animal owner) need to also be reported by the company?	18
3.1.2.15 Do all clinical signs need to be coded according to the VeDDRA codes and terms?	18
3.2 Causality coding	18
3.2.1 What is causality coding?	18
3.2.2 How is this causality association expressed?	18
3.2.3 What factors should be taken into account when assessing the causality of an AE?	18
3.2.4 What is the minimum basis to consider a case to be 'probable'?	18
3.2.5 What is the minimum basis to consider a case to be 'possible'?	19
3.2.6 What is the minimum basis to consider a case to be 'unclassifiable/not assessable'?	19
3.2.7 What is the minimum basis to consider a case to be 'unlikely'?	19
3.2.8 Must human cases be coded?	19
3.2.9 In a case of concurrent use must other companies' products be coded?	19
3.3 Third Country Reporting	20
3.3.1 What is a third country?	20
3.3.2 Must an AE occurring in a third country be reported?	20
3.3.3 Are all AEs occurring in third countries reportable?	20
3.3.4 Who must these third country cases be reported to?	20
3.4 Periodic Safety Update Reports (PSURs)	21
3.4.1 What is a PSUR?	21
3.4.2 What is the purpose of the PSUR?	21
3.4.3 When must a PSUR be submitted?	21
3.4.4 What data must be included in the PSUR?	22
3.4.5 Which AE cases need to be included in the line listing?	22
3.4.6 What data need to be included for an AE reported in the line listing?	22
3.4.7 What time span should the report cover? What is the common birth date?	23
3.4.8 What language should be used?	23
3.4.9 Must sales figures be provided for all MSs?	23
3.4.10 For multiple species' products, how are sales attributed to one species?	23
3.4.11 How can the number of doses applied be calculated?	24

3.4.12 What are the standardised body weights to be used in dose calculation formulae?	24
3.4.13 What AEs need to be included in incidence calculations?	25
3.4.14 Do off-label AEs need to be included in incidence calculations?	25
3.4.15 Is there a standardised terminology to describe incidence rates?	25
3.5 Adverse Events in clinical studies?	25
3.5.1 Must cases occurring in post-authorisation safety studies be reported?	25
3.5.2 How must cases occurring in studies with unlicensed products be handled?	25
4. TOOLS	27
4.1 Qualified Person for Pharmacovigilance (QPPV)	27
4.2 Company pharmacovigilance system	27
4.2.1 Does a company need a PhV system?	27
4.2.2 Does the pharmacovigilance system (adverse event database) need to be digital?	27
4.2.3 Must the system be accessible from within every single EU Member State?	27
4.2.4 Do I have to inform the authorities of how I organise my PhV activities?	28
4.2.5 What are the consequences if I do not fulfil my PhV obligations?	28
4.3 Electronic reporting: EudraVigilance	28
4.3.1 Do I need to report all AEs electronically?	28
4.3.2. How do I submit electronically?	28
4.3.3 What is the purpose of EudraVigilance?	29
4.4 Written procedures on veterinary pharmacovigilance	29
4.4.1 Should every company have a written procedure on veterinary pharmacovigilance?	29
4.4.2 What considerations should be taken into account when writing a procedure on pharmacovigilance?	29
4.4.3 Is it necessary to train relevant company personnel in pharmacovigilance procedures?	29
4.5 Can pharmacovigilance be subject to inspections?	29
5. IMPROVING REPORTING AND COMMUNICATING PHARMACOVIGILANCE INFORMATION	30
5.1 How can reporting be generally improved?	30
5.2 How can customers and end users be convinced of the importance to report?	30
5.3 How can the best information be obtained?	30
5.4 What considerations should be taken into account when communicating with the authorities?	31
5.5 Is internal communication important?	31
5.6 Will my reports be made available to the general public?	31
5.7 Can I communicate my PhV data to the general public?	31
6. LIST OF ABBREVIATIONS	32
7. APPENDIXES	33
Appendix 1: links to the legal texts and other official documents	33
Appendix 2: decision tree when a report is received on an observation after treatment or exposure to a VMP	34